The Histidin-rich Glycoprotein Pro¹⁸⁶/Ser Polymorphism Is not Related to Myocardial Infarction in the ECTIM Study

Summary

The histidin-rich glycoprotein (HRG) may contribute to coronary heart disease as a consequence of its possible thrombophilic properties. To test this hypothesis we have investigated the Pro¹⁸⁶/Ser polymorphism of the HRG gene, which is known to strongly affect plasma HRG levels, in a large multicenter case-control study of myocardial infarction (MI). The results failed to demonstrate any association between the polymorphism and MI or angiographically assessed coronary stenosis.

• References

• 1 Heimburger N, Haupt H, Kranz T, Baudner S. Human serum proteins with a high affinity to carboxymethylcellulose, II: Physico-chemical and immunological characterization of a histidin-rich 3,8S-2-glycoprotein (CM-protein I). Hoppe Seylers Z Physiol Chem 1972; 353: 1130-40.
• 2 Leung LLK, Harpel PC, Nachman RL, Rabellino EM. Histidine-rich glyco-protein is present in human platelets and is released following thrombin stimulation. Blood 1983; 62: 1016-21.
• 3 Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidin-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983; 258: 3803-8.
• 4 Leung LLK. Interaction of histidin-rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986; 77: 1305-11.
• 5 Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidin-rich glycoprotein. J Biol Chem 1980; 255: 10214-22.
• 6 Lerch PG, Nydegger UE, Kuyas C, Haeberli A. Histidin-rich glycoprotein binding to activated platelets. Br J Haematol 1988; 70: 219-24.
• 7 Hennis BC, van Boheemen PA, Wakabayashi S, Koide T, Hoffman JJML, Kievit P, Dooijewaard G, Jansen JG, Kluft C. Identification and genetic analysis of a common molecular variant of histidine-rich glycoprotein with a difference of 2 kD in apparent molecular weight. Thromb Haemost 1995; 74: 1491-6.
• 8 Hennis BC, Boomsma DI, van Boheemen PA, Engesser L, Kievit P, Dooijewaard G, Kluft C. An amino acid polymorphism in histidine-rich glyco-protein (HRG) explains 59% of the variance in plasma HRG levels. Thromb Haemost 1995; 74: 1497-50.
• 9 Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy P, Luc G, Richard JL, Ducimetière P, Cambien F. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM study. Arterioscler Thromb 1992; 12: 701-7.
• 10 WHO MONICA Project principal investigators.. The World Health Organization MONICA project (MONItoring trends and determinants in CArdiovascular disease): A major international collaboration. J Clin Epidemiol 1988; 41: 105-14.
• 11 Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-41.
• 12 Scarabin P-Y, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans A, Samama M, Cambien F. Genetic variation at the -fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM study. Arterioscler Thromb 1993; 13: 886-91.
• 13 Eriksson E, Ranby N, Gyzander E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-d-lysine stimulated assay. Thromb Res 1988; 50: 91-101.
• 14 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 231-7.
• 15 Herrmann S-M, Poirier O, Marques-Vidal P, Evans A, Arveiler A, Luc G, Emmerich J, Cambien F. The Leu³³/Pro polymorphism (Pl^A1/Pl^A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemost 1997; 77: 1179-81.
• 16 Castaman G, Ruggeri M, Burei F, Rodeghiero F. High levels of histidine-rich glycoprotein and thrombotic diathesis. Thromb Res 1993; 69: 297-305.
• 17 Engesser L, Kluft C, Briët E, Brommer EJP. Familial elevation of plasma histidine-rich glycoprotein in a family with thrombophilia. Brit J Haematol 1987; 67: 355-8.
• 18 Falkon L, Gari M, Montserrat I, Borrell M, Fontcuberta J. Familial elevation of histidine-rich glycoprotein. A case associated with recurrent venous thrombosis and high PAI-1 levels. Thromb Res 1992; 66: 265-70.